LIBD

Boehringer Ingelheim and The Lieber Institute for Brain Development to Collaborate to Develop Centrally Acting COMT Inhibitors for Treatment of Neuropsychiatric Disorders

Ingelheim, Germany & Baltimore, Maryland, United States:  Through the partnership with the Lieber Institute, Boehringer Ingelheim obtains access to preclinical…

Read More »